U.S. Stock Futures Slip as Year-End Trading Turns Cautious 
Oil Prices Stabilize at Start of 2026 as OPEC+ Policy and Geopolitical Risks Shape Market Outlook 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Asian Stock Markets Start New Year Higher as Tech and AI Shares Drive Gains 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
China Imposes 55% Tariff on Beef Imports Above Quota to Protect Domestic Industry 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Oil Prices Slide in 2025 as Oversupply and Geopolitical Risks Shape Market Outlook 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Federal Reserve Begins Treasury Bill Purchases to Stabilize Reserves and Money Markets 
U.S. Dollar Steadies Ahead of Fed Minutes as Markets Eye Policy Divisions 
South Korea Factory Output Misses Forecasts in November Amid Ongoing Economic Uncertainty 
Genexine, the South Korean biotechnology company, is said to have made a deal with PT Kalbe Farma, an Indonesian pharmaceutical firm. The contract is about the supply of 10 million doses of the COVID-19 vaccine that it is currently developing.
The vaccine supply deal
The information about Genexine’s agreement with the Indonesian pharma was reported on Tuesday, April 27. While the Korean company is not done yet with the clinical tests for its vaccine brand, PT Kalbe Farma is confident enough for its effectiveness since it already placed an order.
But then again, The Korea Herald pointed out that the deal is not fully done yet. This is because the sale will only be possible if the government of Indonesia will approve the Genexine vaccine for emergency use.
Once everything is ironed out, the purchase of 10 million doses of coronavirus vaccine that Genexine named GX-19NA will be finalized. At this point, it was mentioned that the shot is still in the second phase of the clinical trial. A third one is expected to follow soon.
After the purchase, it was reported that Genexine will be receiving royalties based on sales of the vaccine through PT Kalbe Farma.
Phase 3 of the clinical trial
Genexine and PT Kalbe Farma have submitted applications for the second and third stages of the trials to the Indonesian Food and Drug Authority. The latter will be funding the cost of the clinical studies and since this is the arrangement, Genexine will not be given a downpayment for the order of 10 million doses, Korea Bio Med reported.
They also forwarded an application for an investigational new drug (IND) to the Indonesia National Agency of Drug and Food Control. It has been almost a month since the submission and they are waiting for approval.
"Indonesia has faith in the safety and efficacy of GX-19N, promised to conduct the joint clinical trials, and pre-ordered the vaccine candidate," Woo Jung Won, Genexine’s chief executive officer, said. "We will provide a safer Covid-19 vaccine for Indonesia and Korea through the successful development of GX-19N."
Meanwhile, no serious adverse effects were noted in the clinical trials that have been done so far.
